JP2018509936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509936A5 JP2018509936A5 JP2017567527A JP2017567527A JP2018509936A5 JP 2018509936 A5 JP2018509936 A5 JP 2018509936A5 JP 2017567527 A JP2017567527 A JP 2017567527A JP 2017567527 A JP2017567527 A JP 2017567527A JP 2018509936 A5 JP2018509936 A5 JP 2018509936A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- epitopes
- cell
- colorectal cancer
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010009944 Colon cancer Diseases 0.000 claims 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 229940122985 Peptide agonist Drugs 0.000 claims 6
- 230000000890 antigenic effect Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000002689 Toll-like receptor Human genes 0.000 claims 4
- 108020000411 Toll-like receptor Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 3
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 3
- 102100034256 Mucin-1 Human genes 0.000 claims 3
- 108010008707 Mucin-1 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000000763 Survivin Human genes 0.000 claims 3
- 108010002687 Survivin Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- -1 βhCG Proteins 0.000 claims 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 2
- 241000283070 Equus zebra Species 0.000 claims 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 239000002131 composite material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100038916 Caspase-5 Human genes 0.000 claims 1
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 1
- 101000741072 Homo sapiens Caspase-5 Proteins 0.000 claims 1
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 1
- 101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 claims 1
- 101000801539 Homo sapiens Mitochondrial import receptor subunit TOM34 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 claims 1
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 1
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 1
- 102100033583 Mitochondrial import receptor subunit TOM34 Human genes 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 108091008605 VEGF receptors Proteins 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000009813 cataract 31 multiple types Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2015/000580 | 2015-03-16 | ||
| EP2015000580 | 2015-03-16 | ||
| EP2015002244 | 2015-11-09 | ||
| EPPCT/EP2015/002244 | 2015-11-09 | ||
| PCT/EP2016/000473 WO2016146262A1 (en) | 2015-03-16 | 2016-03-16 | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for treatment of colorectal cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509936A JP2018509936A (ja) | 2018-04-12 |
| JP2018509936A5 true JP2018509936A5 (enExample) | 2019-03-22 |
| JP6993240B2 JP6993240B2 (ja) | 2022-02-15 |
Family
ID=55066559
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567527A Active JP6993240B2 (ja) | 2015-03-16 | 2016-03-16 | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567526A Active JP6862369B2 (ja) | 2015-03-16 | 2016-03-16 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567526A Active JP6862369B2 (ja) | 2015-03-16 | 2016-03-16 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2017567525A Active JP6882207B2 (ja) | 2015-03-16 | 2016-03-16 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021059082A Active JP7179896B2 (ja) | 2015-03-16 | 2021-03-31 | 細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
| JP2021078278A Active JP7190528B2 (ja) | 2015-03-16 | 2021-05-06 | 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20180133327A1 (enExample) |
| EP (4) | EP3270954A1 (enExample) |
| JP (5) | JP6993240B2 (enExample) |
| KR (2) | KR102386172B1 (enExample) |
| CN (1) | CN107428845A (enExample) |
| AU (5) | AU2016232656A1 (enExample) |
| CA (3) | CA2973770A1 (enExample) |
| CL (1) | CL2017002345A1 (enExample) |
| CY (1) | CY1122953T1 (enExample) |
| DK (3) | DK3693009T3 (enExample) |
| EA (1) | EA038049B1 (enExample) |
| ES (3) | ES2978792T3 (enExample) |
| HR (1) | HRP20200491T1 (enExample) |
| HU (3) | HUE048808T2 (enExample) |
| IL (2) | IL253416B (enExample) |
| LT (1) | LT3270955T (enExample) |
| MX (1) | MX2017011796A (enExample) |
| NZ (1) | NZ733762A (enExample) |
| PH (1) | PH12017501287A1 (enExample) |
| PL (3) | PL3693009T3 (enExample) |
| PT (2) | PT3270955T (enExample) |
| RS (1) | RS60089B1 (enExample) |
| SI (1) | SI3270955T1 (enExample) |
| WO (5) | WO2016146143A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| ES2907489T3 (es) | 2015-12-14 | 2022-04-25 | X4 Pharmaceuticals Inc | Métodos para el tratamiento del cáncer |
| WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| HUE060517T2 (hu) | 2015-12-22 | 2023-03-28 | X4 Pharmaceuticals Inc | Immunhiányos betegség kezelésére szolgáló eljárások |
| PT3429618T (pt) | 2016-03-16 | 2024-04-02 | Amal Therapeutics Sa | Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| IL265479B (en) | 2016-09-21 | 2022-09-01 | Amal Therapeutics Sa | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| CN110049774A (zh) | 2016-10-07 | 2019-07-23 | 恩特罗姆公司 | 肿瘤相关抗原表位的小型生物群序列变体 |
| CA3040194A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| WO2018078620A1 (en) * | 2016-10-25 | 2018-05-03 | Urogen Pharma Ltd. | Immunomodulating treatments of body cavities |
| US11229668B2 (en) * | 2017-02-07 | 2022-01-25 | Nantcell, Inc. | Maximizing T-cell memory and compositions and methods therefor |
| CA3057715A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| US11433128B2 (en) * | 2017-04-07 | 2022-09-06 | Tianxin Wang | Cell surface anchoring antigen conjugates to treat cancer |
| US12121573B2 (en) | 2019-07-14 | 2024-10-22 | Tianxin Wang | Methods and agents including STING agonist to treat tumor |
| WO2018197926A1 (en) * | 2017-04-26 | 2018-11-01 | Robert Penchovsky | Methods for creating novel antibacterial agents using chimeric antisense oligonucleotides |
| JP2020525427A (ja) * | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| WO2019134018A1 (en) * | 2018-01-05 | 2019-07-11 | Telethon Kids Institute | Vaccine conjugates and uses thereof |
| WO2019160780A1 (en) * | 2018-02-16 | 2019-08-22 | Wang tian xin | Methods and agents to treat tumor cells and cancer |
| DK3773689T5 (da) | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| JP7370598B2 (ja) * | 2018-05-02 | 2023-10-30 | 国立大学法人 新潟大学 | ペプチド及びその使用 |
| EP3566718A1 (en) | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| CN120843603A (zh) | 2018-07-11 | 2025-10-28 | 布里格姆妇女医院 | 用于跨血脑屏障递送试剂的方法和组合物 |
| EP3829652A4 (en) * | 2018-08-01 | 2022-05-11 | University of Maryland, Baltimore | MODULATION OF MTORC1 ACTIVITY AND AUTOPHAGY BY CIB2-RHEB INTERACTION |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3876956A4 (en) * | 2018-11-08 | 2022-12-28 | The Regents of The University of California | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS |
| BR112021009111A2 (pt) | 2018-11-16 | 2021-08-24 | Bristol-Myers Squibb Company | Anticorpos anti-nkg2a e usos dos mesmos |
| WO2020130547A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 엘알알씨24 단백질 유래 세포막 투과 도메인 |
| WO2020130548A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 쥐피에이티씨에치4 단백질 유래 세포막 투과 도메인 |
| KR102351041B1 (ko) | 2018-12-19 | 2022-01-13 | 한국화학연구원 | 인간 lrrc24 단백질 유래 세포막 투과 도메인 |
| WO2020130546A1 (ko) * | 2018-12-19 | 2020-06-25 | 한국화학연구원 | 인간 씨엘케이2 단백질 유래 세포막 투과 도메인 |
| CN113557035B (zh) * | 2019-01-12 | 2025-09-05 | 卫理公会医院 | 自组装肽纳米颗粒和其用途 |
| CN109859795A (zh) * | 2019-02-20 | 2019-06-07 | 成都分迪科技有限公司 | 泛素化降解目标蛋白质的数据库 |
| WO2020198734A1 (en) * | 2019-03-28 | 2020-10-01 | The Penn State Research Foundation | Methods, compositions relating to treatment of cancer |
| US11339190B2 (en) | 2020-04-21 | 2022-05-24 | Rush University Medical Center | Peptides for the treatment of covid-19 |
| US11667678B2 (en) | 2019-04-21 | 2023-06-06 | Rush University Medical Center | Peptides for the treatment of COVID-19 |
| CA3138597A1 (en) | 2019-05-10 | 2020-11-19 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| JP7839733B2 (ja) * | 2020-01-10 | 2026-04-02 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 脳腫瘍を処置するための血液脳関門を横断する免疫療法剤を送達するための方法および組成物 |
| JP2023517956A (ja) | 2020-03-10 | 2023-04-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 好中球減少症を処置する方法 |
| KR102484312B1 (ko) * | 2020-05-14 | 2023-01-02 | 한국화학연구원 | 고효능 사스 코로나바이러스 2 항원 및 이를 포함하는 백신 조성물 |
| CA3180665A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| JP7598660B2 (ja) * | 2020-06-04 | 2024-12-12 | ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション | フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物 |
| EP4171619A4 (en) * | 2020-06-26 | 2024-08-07 | National Breast Cancer Coalition | BREAST CANCER VACCINE |
| EP4210734A1 (en) | 2020-09-14 | 2023-07-19 | Boehringer Ingelheim International GmbH | Heterologous prime boost vaccine |
| KR102556731B1 (ko) * | 2020-09-29 | 2023-07-21 | 주식회사 젠센 | 단백질 수송 도메인, 이를 포함하는 융합 화합물 및 이 융합 화합물을 포함하는 약학 조성물 |
| JP2023545178A (ja) * | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN113817677B (zh) * | 2021-09-29 | 2023-08-18 | 四川大学 | 泛酸或其衍生物与α-D-葡萄糖-1,6-二磷酸或其衍生物在促进DC迁移中的用途 |
| WO2023059687A1 (en) * | 2021-10-06 | 2023-04-13 | Whispergenics, Inc. | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of cancers |
| KR102514849B1 (ko) * | 2021-10-28 | 2023-03-28 | 전남대학교산학협력단 | 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물 |
| EP4493209A1 (en) | 2022-03-16 | 2025-01-22 | Boehringer Ingelheim International GmbH | Tumor antigens, compounds comprising the tumor antigens kras, tpx2 or aurka and uses thereof |
| AU2023251864A1 (en) * | 2022-04-13 | 2024-10-03 | The Regents Of The University Of California | Immune cell inhibition by immune checkpoint engagers |
| FR3143031A1 (fr) * | 2022-12-08 | 2024-06-14 | Université Grenoble Alpes | Nouveaux peptides et leur utilisation en tant que transporteurs pour l’internalisation de molécules d’intérêt dans des cellules cibles |
| WO2024197792A1 (en) * | 2023-03-31 | 2024-10-03 | Beijing University Of Chinese Medicine | A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof |
| WO2025262719A1 (en) * | 2024-06-21 | 2025-12-26 | Centre For Dna Fingerprinting And Diagnostics | A composition for treating cancer, methods and use thereof |
| CN119925590A (zh) * | 2025-04-08 | 2025-05-06 | 北京华诺泰生物医药科技有限公司 | 一种mpl复合佐剂及其制备方法和应用 |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN1254541C (zh) | 2000-02-23 | 2006-05-03 | 史密丝克莱恩比彻姆生物有限公司 | 新化合物 |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| EP1677820B1 (en) * | 2003-10-15 | 2012-04-04 | Istituto Superiore Di Sanita' | Colorectal cancer antigen |
| WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
| JP5112863B2 (ja) | 2004-07-01 | 2013-01-09 | ノヴォ ノルディスク アー／エス | ヒト抗−ｋｉｒ抗体 |
| US20120052080A1 (en) | 2004-09-21 | 2012-03-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| JP2008528643A (ja) * | 2005-02-04 | 2008-07-31 | スルバック アーぺーエス | サバイビンペプチドワクチン |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| CA2947292C (en) | 2006-12-27 | 2019-07-23 | Emory University | Compositions and methods for the treatment of infections and tumors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| DK2183361T3 (en) * | 2007-07-27 | 2015-07-27 | Immatics Biotechnologies Gmbh | Novel immunotherapy against brain tumors |
| CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP2011519834A (ja) * | 2008-04-25 | 2011-07-14 | インスティチュート フォー システムズ バイオロジー | フラジェリンポリペプチドワクチン |
| RS53872B2 (sr) | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| DK3156069T3 (da) | 2008-06-20 | 2020-09-21 | Univ Duke | Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010105347A1 (en) | 2009-03-16 | 2010-09-23 | Mcmaster University | Vaccination methods |
| NZ596501A (en) | 2009-05-27 | 2013-11-29 | Glaxosmithkline Biolog Sa | Casb7439 constructs |
| IN2012DN00863A (enExample) | 2009-07-31 | 2015-07-10 | Medarex Inc | |
| CA2772204A1 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| JP5964233B2 (ja) * | 2009-09-11 | 2016-08-03 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． | Ｈｐｖにより惹起される疾患の治療用組成物 |
| WO2011036211A1 (en) * | 2009-09-23 | 2011-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9175048B2 (en) | 2010-04-26 | 2015-11-03 | Universite Joseph Fourier | Use of peptides as transporters intended for the internalization of molecules of interest into target cells |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| US8968746B2 (en) | 2010-07-30 | 2015-03-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| BR112013005970A2 (pt) * | 2010-09-14 | 2016-07-05 | Council Scient Ind Res | imunógeno sintético, últil para gerar imunidade duradoura e proteção contra patógenos. |
| WO2012048190A1 (en) * | 2010-10-08 | 2012-04-12 | Regents Of The University Of Minnesota | Annexin ii compositions and methods |
| KR101760464B1 (ko) * | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| KR20140030132A (ko) | 2011-01-10 | 2014-03-11 | 클리브랜드 바이오랩스, 아이엔씨. | 암을 치료하기 위한 톨-유사 수용체 효능제의 용도 |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| US8795678B2 (en) * | 2011-05-13 | 2014-08-05 | Academia Sinica | TLR-2 agonists and methods of use thereof |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| US8819679B2 (en) | 2011-07-28 | 2014-08-26 | International Business Machines Corporation | Methods and systems for on-boarding applications to a cloud |
| WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| HK1202252A1 (en) * | 2011-11-16 | 2015-09-25 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120073A1 (en) * | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| CN109806387B (zh) | 2012-07-13 | 2022-03-04 | S-目标疗法有限公司 | 免疫调节疫苗 |
| WO2014165101A1 (en) * | 2013-03-13 | 2014-10-09 | California Stem Cell, Inc. | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| WO2014041505A1 (en) * | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
| PT2897620T (pt) | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
| WO2014070663A1 (en) * | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| JP2016537027A (ja) * | 2013-11-06 | 2016-12-01 | ソルスティス バイオロジクス，リミティッド | ジスルフィド基を有するポリヌクレオチド構築物 |
| ES2928331T3 (es) * | 2013-11-13 | 2022-11-17 | Univ Minnesota | Composiciones de variantes de anexina II y métodos |
| SG10201805674YA (en) * | 2014-01-02 | 2018-08-30 | Memorial Sloan Kettering Cancer Center | Determinants of cancer response to immunotherapy |
| EP3152308A4 (en) * | 2014-06-06 | 2017-12-27 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| RU2739794C2 (ru) | 2014-10-31 | 2020-12-28 | Массачусетс Инститьют Оф Текнолоджи | Доставка биомолекул в клетки иммунной системы |
| EP4098278A1 (en) | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| JPWO2017002345A1 (ja) | 2015-06-29 | 2018-04-19 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017118866A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Engineered virus |
| AU2017207532A1 (en) | 2016-01-11 | 2018-08-16 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| PT3429618T (pt) * | 2016-03-16 | 2024-04-02 | Amal Therapeutics Sa | Combinação de um modulador de ponto de controlo imunitário e um complexo que compreende um péptido de penetração celular, uma carga e um agonistra peptídico de tlr para utilização em medicina |
| JP2019514988A (ja) | 2016-05-09 | 2019-06-06 | ターンストーン リミテッド パートナーシップ | 組合せプライム：ブースト療法 |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| US11052149B2 (en) | 2016-09-19 | 2021-07-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| IL265479B (en) | 2016-09-21 | 2022-09-01 | Amal Therapeutics Sa | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy |
| JP7457642B2 (ja) | 2017-04-03 | 2024-03-28 | ビオンテック ユーエス インコーポレイテッド | タンパク質抗原およびその使用 |
| CN111936156A (zh) | 2018-02-02 | 2020-11-13 | 诺华股份有限公司 | 用于治疗癌症的STING激动剂和IL-15/IL15-Ra的组合 |
| WO2019246450A1 (en) | 2018-06-20 | 2019-12-26 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| EP4210734A1 (en) | 2020-09-14 | 2023-07-19 | Boehringer Ingelheim International GmbH | Heterologous prime boost vaccine |
| JP2023545178A (ja) | 2020-10-14 | 2023-10-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｔｉｎｇアゴニストと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
-
2015
- 2015-12-22 WO PCT/EP2015/002598 patent/WO2016146143A1/en not_active Ceased
- 2015-12-22 US US15/557,653 patent/US20180133327A1/en not_active Abandoned
-
2016
- 2016-03-16 EA EA201792045A patent/EA038049B1/ru unknown
- 2016-03-16 PT PT167115294T patent/PT3270955T/pt unknown
- 2016-03-16 JP JP2017567527A patent/JP6993240B2/ja active Active
- 2016-03-16 JP JP2017567526A patent/JP6862369B2/ja active Active
- 2016-03-16 HU HUE16713731A patent/HUE048808T2/hu unknown
- 2016-03-16 ES ES19219165T patent/ES2978792T3/es active Active
- 2016-03-16 KR KR1020217003158A patent/KR102386172B1/ko active Active
- 2016-03-16 HU HUE16711529A patent/HUE048807T2/hu unknown
- 2016-03-16 ES ES16713731T patent/ES2781455T3/es active Active
- 2016-03-16 EP EP16711528.6A patent/EP3270954A1/en active Pending
- 2016-03-16 HU HUE19219165A patent/HUE066851T2/hu unknown
- 2016-03-16 PL PL19219165.8T patent/PL3693009T3/pl unknown
- 2016-03-16 JP JP2017567525A patent/JP6882207B2/ja active Active
- 2016-03-16 EP EP16711529.4A patent/EP3270955B1/en active Active
- 2016-03-16 WO PCT/EP2016/000471 patent/WO2016146260A1/en not_active Ceased
- 2016-03-16 DK DK19219165.8T patent/DK3693009T3/da active
- 2016-03-16 WO PCT/EP2016/000470 patent/WO2016146259A1/en not_active Ceased
- 2016-03-16 EP EP19219165.8A patent/EP3693009B1/en active Active
- 2016-03-16 DK DK16711529.4T patent/DK3270955T3/da active
- 2016-03-16 RS RS20200337A patent/RS60089B1/sr unknown
- 2016-03-16 AU AU2016232656A patent/AU2016232656A1/en not_active Abandoned
- 2016-03-16 CA CA2973770A patent/CA2973770A1/en active Pending
- 2016-03-16 DK DK16713731.4T patent/DK3270957T3/da active
- 2016-03-16 KR KR1020177029623A patent/KR102212451B1/ko active Active
- 2016-03-16 ES ES16711529T patent/ES2781454T3/es active Active
- 2016-03-16 LT LTEP16711529.4T patent/LT3270955T/lt unknown
- 2016-03-16 WO PCT/EP2016/000472 patent/WO2016146261A1/en not_active Ceased
- 2016-03-16 CA CA2973747A patent/CA2973747A1/en active Pending
- 2016-03-16 NZ NZ733762A patent/NZ733762A/en unknown
- 2016-03-16 US US15/557,649 patent/US20180133338A1/en not_active Abandoned
- 2016-03-16 WO PCT/EP2016/000473 patent/WO2016146262A1/en not_active Ceased
- 2016-03-16 HR HRP20200491TT patent/HRP20200491T1/hr unknown
- 2016-03-16 CA CA2973757A patent/CA2973757A1/en active Pending
- 2016-03-16 CN CN201680015946.2A patent/CN107428845A/zh active Pending
- 2016-03-16 US US15/557,651 patent/US20180133339A1/en not_active Abandoned
- 2016-03-16 AU AU2016232659A patent/AU2016232659B2/en active Active
- 2016-03-16 SI SI201630654T patent/SI3270955T1/sl unknown
- 2016-03-16 PL PL16713731T patent/PL3270957T3/pl unknown
- 2016-03-16 PT PT167137314T patent/PT3270957T/pt unknown
- 2016-03-16 EP EP16713731.4A patent/EP3270957B1/en active Active
- 2016-03-16 PL PL16711529T patent/PL3270955T3/pl unknown
- 2016-03-16 MX MX2017011796A patent/MX2017011796A/es unknown
- 2016-03-16 US US15/557,647 patent/US20180133295A1/en not_active Abandoned
- 2016-03-16 AU AU2016232657A patent/AU2016232657B9/en active Active
-
2017
- 2017-07-11 IL IL253416A patent/IL253416B/en unknown
- 2017-07-14 PH PH12017501287A patent/PH12017501287A1/en unknown
- 2017-09-15 CL CL2017002345A patent/CL2017002345A1/es unknown
-
2020
- 2020-04-07 CY CY20201100327T patent/CY1122953T1/el unknown
-
2021
- 2021-03-31 JP JP2021059082A patent/JP7179896B2/ja active Active
- 2021-05-06 JP JP2021078278A patent/JP7190528B2/ja active Active
- 2021-08-01 IL IL285273A patent/IL285273B/en unknown
- 2021-08-06 US US17/396,351 patent/US12178788B2/en active Active
- 2021-08-09 US US17/397,447 patent/US12220450B2/en active Active
- 2021-08-18 AU AU2021218097A patent/AU2021218097B2/en active Active
- 2021-12-09 AU AU2021282506A patent/AU2021282506B2/en active Active
- 2021-12-22 US US17/558,906 patent/US12453762B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510215A5 (enExample) | ||
| HRP20200491T1 (hr) | Novi kompleks koji sadrži peptid koji prodire u stanicu, teretni i tlr peptidni agonist za liječenje kolorektalnog karcinoma | |
| JP2019528693A5 (enExample) | ||
| JP2018509935A5 (enExample) | ||
| Liu et al. | Cancer vaccines as promising immuno-therapeutics: platforms and current progress | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2016501829A5 (enExample) | ||
| AR121588A2 (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer | |
| AR121383A2 (es) | Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres | |
| JP2019515650A5 (enExample) | ||
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| PE20240645A1 (es) | Peptido inmunogenico derivado de moleculas de antigenos leucocitarios humanos (hla) como biomarcador en la inmunoterapia de diversos tumores | |
| EP3545965A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| JP2018509163A5 (enExample) | ||
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| RU2015113378A (ru) | Новые проникающие в клетку пептиды | |
| JP2016530290A5 (enExample) | ||
| JP2019520038A5 (enExample) | ||
| JP2014502961A5 (enExample) | ||
| CN116348137A (zh) | 异源初免加强疫苗 | |
| RU2015143164A (ru) | Пептиды kntc2 и содержащие их вакцины | |
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| JP2018528960A5 (enExample) | ||
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| JP2020526202A5 (enExample) |